RxDoctor Payments Data

Jeff Steinhoff, MD

Cardiovascular Disease · Largo, FLNPI 1811959869

Payments from drug & device makers

$61,964in general payments, 2019–2025

Across 654 payments — averaging $94.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$11K
  • Sanofi-aventis U.S. LLC$11K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • Amgen$7K
  • Abbott$4K
  • Regeneron Healthcare Solutions, Inc.$4K
  • plus $16K from 46 others

What the payments were for

  • Speaking & faculty fees$18,45747%
  • Travel & lodging$1,7554%
  • Food & beverage$19,36049%
  • Education$630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,964 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$171,113
Medicare patients
668
Services billed
2,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$213,286
XareltoRivaroxaban151$175,623
EntrestoSacubitril/Valsartan135$151,635
Repatha SureclickEvolocumab97$112,412
FarxigaDapagliflozin Propanediol79$95,014
JardianceEmpagliflozin74$80,494
VascepaIcosapent Ethyl38$31,021
BrilintaTicagrelor27$28,004
Repatha SyringeEvolocumab11$12,181
Atorvastatin Calcium813$8,374
Praluent PenAlirocumab14$6,954
Metoprolol Succinate302$4,645
ClopidogrelClopidogrel Bisulfate355$4,192
Ezetimibe228$3,790
Rosuvastatin Calcium268$3,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$721$213,286178 claims
Johnson & JohnsonXarelto$1,311$175,623151 claims
NovartisEntresto$3,863$151,635135 claims
AstraZenecaFarxiga, Brilinta$11,409$123,018106 claims
Boehringer IngelheimJardiance$507$80,49474 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →